

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



Final Appraisal Recommendation

Advice No: 0813 – May 2013

**Acridinium bromide (Eklira® Genuair®) 322 micrograms
inhalation powder**

Submission by AstraZeneca UK Ltd

Recommendation of the All Wales Medicines Strategy Group

Acridinium bromide (Eklira® Genuair®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 938), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in August 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation 0813: Acridinium bromide (Eklira® Genuair®) 322 micrograms inhalation powder. May 2013.